Rehab Research Rendezvous: Join the Hybrid Health Chat
Published Date: 3/12/2026
Notice
Summary
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is hosting a hybrid meeting on December 7-8, 2026, about medical rehabilitation research. Anyone interested can join in person or online, share ideas, or even speak at the meeting. This is a great chance for researchers, patients, and advocates to get involved and learn about new research and policies—no registration needed!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Hybrid public meeting — no registration
The National Advisory Board on Medical Rehabilitation Research will hold a hybrid public meeting on December 7-8, 2026 (Dec 7: 10:00 a.m. to 3:00 p.m.; Dec 8: 10:00 a.m. to 2:00 p.m.) at 6710 B Rockledge Drive, Bethesda, MD, and online via NIH Videocast (https://videocast.nih.gov/). Registration is not required to attend in person or virtually.
How to give written or oral comments
Any member of the public may file written comments by sending a statement with name, address, telephone number, and affiliation to the listed Contact Person. To present oral comments, you must notify the Contact Person at least 10 days before the meeting, submit a letter of intent and brief description, and (if accepted) presentations may be limited to five minutes with only one representative per organization.
Accommodations for attendees with special needs
Individuals who plan to attend in person or view the virtual meeting and need special assistance or reasonable accommodation should notify the Contact Person listed in advance of the meeting.
On-campus entry and ID requirements
Visitors attending the meeting on campus will be subject to NIH security procedures: visitor vehicles (including taxis and shuttles) will be inspected before being allowed on campus, and visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and state the purpose of their visit.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2026-04859, Department of Defense Wage Committee; Notice of Federal Advisory Committee Meeting
The Department of Defense Wage Committee met several times to review and update pay rates for blue-collar workers in different areas. These changes affect DoD employees paid from government funds and could impact their wages soon. The meetings were private and focused on making sure pay stays fair and up-to-date.
Next: 2026-04861, Notice of Continuation and Request for Applications for the Industry Trade Advisory Committees
The U.S. government is renewing the Industry Trade Advisory Committees (ITACs) for another four years and is looking for new members to join. If you’re interested in helping shape trade policies and agreements, apply by April 2, 2026. This is a great chance for qualified folks to influence important trade decisions and be part of a key advisory team.